Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation

Molecular Therapy

Volumn 22, Issue 1, 2014, Pages 196-205

  Johnson, Teresa R ^a   Rangel, David ^a   Graham, Barney S ^b   Brough, Douglas E ^a   Gall, Jason G ^a  

^a GENVEC INC   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; GENETIC IMMUNIZATION; GRANULOCYTE; IMMUNOGENICITY; INFECTION PREVENTION; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG INFILTRATE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEROPREVALENCE; SINGLE DRUG DOSE; VIRAL GENE THERAPY; VIRUS GENE; VIRUS ISOLATION;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MUS; PRIMATES; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; SIGMODON;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; LUNG; MICE; NOSE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 84891825171     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.142     Document Type: Article

References (45)

1. Collins, PL and Graham, BS (2008). Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82: 2040-2055
2. Nair, H, Nokes, DJ, Gessner, BD, Dherani, M, Madhi, SA, Singleton, RJ et al. (2010). Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375: 1545-1555
3. Hall, CB, Weinberg, GA, Iwane, MK, Blumkin, AK, Edwards, KM, Staat, MA et al. (2009). The burden of respiratory syncytial virus infection in young children. N Engl J Med 360: 588-598
4. Falsey, AR, Hennessey, PA, Formica, MA, Cox, C and Walsh, EE (2005). Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352: 1749- 1759
5. Small, TN, Casson, A, Malak, SF, Boulad, F, Kiehn, TE, Stiles, J et al. (2002). Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 29: 321-327
6. Hall, CB (2012). The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets 12: 92-97
7. Kim, HW, Canchola, JG, Brandt, CD, Pyles, G, Chanock, RM, Jensen, K et al. (1969). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434
8. Hurwitz, JL (2011). Respiratory syncytial virus vaccine development. Expert Rev Vaccines 10: 1415-1433
9. Henderson, FW, Collier, AM, Clyde, WA Jr and Denny, FW (1979). Respiratorysyncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 300: 530-534
10. van Drunen Littel-Van Den Hurk, S and Watkiss, ER (2012). Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2: 300-305
11. Prince, GA, Horswood, RL, Camargo, E, Koenig, D and Chanock, RM (1983). Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun 42: 81-87
12. Ochola, R, Sande, C, Fegan, G, Scott, PD, Medley, GF, Cane, PA et al. (2009). The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS ONE 4: E8088
13. Johnson, S, Oliver, C, Prince, GA, Hemming, VG, Pfarr, DS, Wang, SC et al. (1997). Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215-1224
14. Van Kampen, KR, Shi, Z, Gao, P, Zhang, J, Foster, KW, Chen, DT et al. (2005). Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23: 1029-1036
15. Catanzaro, AT, Koup, RA, Roederer, M, Bailer, RT, Enama, ME, Moodie, Z et al. (2006). Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194: 1638-1649
16. Fu, Y, He, J, Zheng, X, Wu, Q, Zhang, M, Wang, X et al. (2009). Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem Biophys Res Commun 381: 528-532
17. Kohlmann, R, Schwannecke, S, Tippler, B, Ternette, N, Temchura, VV, Tenbusch, M et al. (2009). Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 83: 12601-12610
18. Yu, JR, Kim, S, Lee, JB and Chang, J (2008). Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 82: 2350-2357
19. Abbink, P, Lemckert, AA, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663
20. Shiver, JW and Emini, EA (2004). Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55: 355-372
21. Fattori, E, Zampaglione, I, Arcuri, M, Meola, A, Ercole, BB, Cirillo, A et al. (2006).Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther 13: 1088-1096
22. Xiang, Z, Gao, G, Reyes-Sandoval, A, Cohen, CJ, Li, Y, Bergelson, JM et al. (2002). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76: 2667-2675
23. Colloca, S, Barnes, E, Folgori, A, Ammendola, V, Capone, S, Cirillo, A et al. (2012). Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 115ra112
24. Barnes, E, Folgori, A, Capone, S, Swadling, L, Aston, S, Kurioka, A et al. (2012). Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra111
25. Sheehy, SH, Duncan, CJ, Elias, SC, Collins, KA, Ewer, KJ, Spencer, AJ et al. (2011). Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269-2276
26. Walsh, EE, Brandriss, MW and Schlesinger, JJ (1987). Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J Gen Virol 68 (Pt 8): 2169-2176
27. Kahl, CA, Bonnell, J, Hiriyanna, S, Fultz, M, Nyberg-Hoffman, C, Chen, P et al. (2010). Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 28: 5691-5702
28. Murphy, BR, Sotnikov, A, Paradiso, PR, Hildreth, SW, Jenson, AB, Baggs, RB et al. (1989). Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7: 533-540
29. Prince, GA, Curtis, SJ, Yim, KC and Porter, DD (2001). Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82(Pt 12): 2881-2888
30. Mascola, JR, Snyder, SW, Weislow, OS, Belay, SM, Belshe, RB, Schwartz, DH et al. (1996). Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173: 340-348
31. Martin, NC, Pardo, J, Simmons, M, Tjaden, JA, Widjaja, S, Marovich, MA et al. (2006). An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods 134: 74-85
32. Stokes, KL, Chi, MH, Sakamoto, K, Newcomb, DC, Currier, MG, Huckabee, MM et al. (2011). Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol 85: 5782-5793
33. Matheson, JW, Rich, FJ, Cohet, C, Grimwood, K, Huang, QS, Penny, D et al. (2006). Distinct patterns of evolution between respiratory syncytial virus subgroups A and B from New Zealand isolates collected over thirty-seven years. J Med Virol 78: 1354-1364
34. Murphy, BR, Prince, GA, Walsh, EE, Kim, HW, Parrott, RH, Hemming, VG et al. (1986). Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24: 197-202
35. Baden, LR, Walsh, SR, Seaman, MS, Tucker, RP, Krause, KH, Patel, A et al. (2013). Firstin- human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207: 240-247
36. Graham, BS (2011). Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239: 149-166
37. Wang, Y, Xiang, Z, Pasquini, S and Ertl, HC (1997). The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. J Virol 71: 3677-3683
38. Levely, ME, Bannow, CA, Smith, CW and Nicholas, JA (1991). Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. J Virol 65: 3789-3796
39. Srikiatkhachorn, A, Chang, W and Braciale, TJ (1999). Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J Virol 73: 6590-6597
40. Hull, RN, Minner, JR and Mascoli, CC (1958). New viral agents recovered from tissue cultures of monkey kidney cells. III. Recovery of additional agents both from cultures of monkey tissues and directly from tissues and excreta. Am J Hyg 68: 31-44
41. Brough, DE, Lizonova, A, Hsu, C, Kulesa, VA and Kovesdi, I (1996). A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 70: 6497-6501
42. Graham, BS, Perkins, MD, Wright, PF and Karzon, DT (1988). Primary respiratory syncytial virus infection in mice. J Med Virol 26: 153-162
43. Chang, J, Srikiatkhachorn, A and Braciale, TJ (2001). Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. J Immunol 167: 4254-4260
44. Kulkarni, AB, Morse, HC 3rd, Bennink, JR, Yewdell, JW and Murphy, BR (1993).Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells. J Virol 67: 4086-4092
45. Blanco, JC, Richardson, JY, Darnell, ME, Rowzee, A, Pletneva, L, Porter, DD et al. (2002). Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. J Infect Dis 185: 1780-1785